
Scott Requadt
CEO Consulate General of Canada (CTA Boston)
- Boston MA
Scott Requadt has operating and investment experience in the biopharmaceutical industry including therapeutics, medtech and diagnostics.

Consulate General of Canada (CTA Boston)
View more experts managed by Consulate General of Canada (CTA Boston)
Social
Biography
Industry Expertise
Areas of Expertise
Education
Harvard Business School
M.B.A.
Business Administration
2001
University of Toronto Law School
L.L.B.
1993
McGill University
B.Comm
Economics & Finance
1990
Selected Media Appearances
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
Business Wire online
2019-10-23
“Living donor kidney transplants save lives. However, they have a downside: the lifelong regimen of immunosuppressive drugs that organ transplant recipients must take elevates their risks of hypertension, high cholesterol, type 2 diabetes, sleep and CNS disorders, infections and certain cancers. Moreover, immunosuppressive drugs are, themselves, toxic to the kidney, leading to declining kidney function over time. On average, a transplanted kidney only lasts between 12-15 years, and many kidney transplant recipients will require multiple transplants over their lifetime,” said Scott Requadt, Chief Executive Officer of Talaris. “In our Phase 2 clinical trial, FCR001 demonstrated the capability to durably free a high percentage of LDKT recipients from immunosuppression and improve their overall quality of life post-transplant, findings which we now hope to reproduce in a larger group of patients in this Phase 3 trial as we advance this potentially transformative therapy...”
FDA approves next phase of medical breakthrough in kidney transplants
WDRB online
2019-10-31
Scott Requadt, the company's CEO, said that patients who started Talaris' trial 10 years ago have not had to take immunosuppessants the entire time...
Investigational Cell Therapy FCR001 Shows Promise for Preventing Post-transplant Kidney Failure
Alport Syndrome News online
2019-11-11
“We’re very excited by this demonstration of the potential of FCR001 to durably reset the immune system and halt autoimmune disease in patients in our Phase 2 trial. Many autoimmune diseases of the kidney are not resolved by a conventional kidney transplant, and therefore patients may require multiple transplants over the course of their lives. We’re hopeful that our cell therapy could interrupt this cycle of repeat transplants,” Scott Requadt, Talaris’ CEO, said in a press release...